本文關(guān)鍵詞：改良三甲散治療老年性癡呆病的免疫炎癥機制研究　出處：《南京中醫(yī)藥大學(xué)》2016年碩士論文　論文類型：學(xué)位論文

  更多相關(guān)文章： 改良三甲散 老年性癡呆病 BV2細(xì)胞 PC12細(xì)胞

【摘要】：老年性癡呆病又稱為阿爾茨海默病(Alzheimer's dementia, AD),是以認(rèn)知功能障礙、精神行為異常和社會功能減退為主要特點的臨床常見的神經(jīng)退行性疾病,其病因迄今仍不清楚,發(fā)病機制尚不完全明確,對于本病目前尚無特效的治療方法。中醫(yī)學(xué)對本病的認(rèn)識歷史悠久,認(rèn)為本病屬本虛標(biāo)實之證,本虛多為肝腎虧虛、髓海不充、心脾不足,標(biāo)實多為氣滯血瘀,痰阻脈絡(luò),導(dǎo)致使清竅失靈,神機失用,發(fā)為癡呆。本文從理論和實驗兩方面論述了改良三甲散治療老年性癡呆病的理論基礎(chǔ)及作用機制。理論研究部分回顧了中醫(yī)學(xué)和西醫(yī)學(xué)對老年性癡呆病的認(rèn)識以及改良三甲散治療老年性癡呆病的前期研究成果。實驗部分以BV2細(xì)胞及PC12細(xì)胞為研究對象,將BV2細(xì)胞分為空白對照組、模型組、改良三甲散高、中、低劑量組、石杉堿甲組,待細(xì)胞貼壁后改良三甲散組及石杉堿甲組分別加入不同濃度的含藥腦脊液,37℃C孵育2h后除空白對照組外均加入LPS(終濃度為1 μg/ml),繼續(xù)孵育24h后收集培養(yǎng)上清,提取蛋白樣品。應(yīng)用硝酸還原酶法檢測各組細(xì)胞培養(yǎng)液中NO的含量；應(yīng)用ELISA法檢測各組細(xì)胞培養(yǎng)液中iNOS、IL-1β、TNF-α的含量；應(yīng)用Western blot法檢測各組細(xì)胞JNK、p-JNK的表達。并以各組BV2細(xì)胞培養(yǎng)液作為條件培養(yǎng)液,作用于PC12細(xì)胞,24小時后提取蛋白樣品,應(yīng)用Western blot法檢測PC12細(xì)胞中APP及BACE的表達情況。實驗結(jié)果顯示,與模型組相比,改良三甲散含藥腦脊液高、中劑量組NO、iNOS、IL-1β、TNF-α的含量均顯著減少(P0.05), p-JNK表達下調(diào)；改良三甲散高、中、低劑量組APP表達下調(diào),改良三甲散中、低劑量組BACE表達下調(diào)。這提示改良三甲散含藥腦脊液可以通過抑制JNK的磷酸化,減少炎性介質(zhì)和細(xì)胞因子的釋放,從而減輕激活的BV2細(xì)胞對PC12細(xì)胞的毒性作用。這可能是改良三甲散治療老年性癡呆病的作用機制之一。
[Abstract]:Alzheimer's disease, also known as Alzheimer's disease, Alzheimer's dementia, is based on cognitive dysfunction. The etiology and pathogenesis of neurodegenerative diseases, which are mainly characterized by mental and behavioral disorders and social dysfunction, are still unclear. For this disease there is no special treatment. Traditional Chinese medicine has a long history of understanding of this disease, think that this disease is a deficiency of the syndrome, the deficiency of the liver and kidney deficiency, deficiency of the marrow sea, heart and spleen insufficiency, the standard of qi stagnation and blood stasis. Phlegm obstructs the choroid, causes clear orifices to be out of order, the spirit machine loses use. In this paper, the theoretical basis and mechanism of modified Sanjia Powder in the treatment of Alzheimer's disease are discussed from the aspects of theory and experiment. The theoretical research part reviews the understanding of Alzheimer's disease in traditional Chinese medicine and western medicine. And the early research results of modified Sanjia Powder in the treatment of Alzheimer's disease. The experimental part of BV2 cells and PC12 cells as the research object. BV2 cells were divided into blank control group, model group, modified Sanjia powder high, medium, low dose group, Huperzine A group. The modified Sanjia Powder group and Huperzine A group were incubated with different concentrations of CSF at 37 鈩，

本文編號：1362862